Description
Humana Press Camptothecins in Cancer Therapy 1st Editon 2005 Hardbound by Val R. Adams
A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance. Biochemistry, Pharmacology, and Chemistry.- Mechanism of Action of Topoisomerase 1 Poisons.- Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage.- Inhibitors of Topoisomerase I Function.- Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors.- Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage.- Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs.- Mechanisms of Resistance to Camptothecins.- Recent Advances in Camptothecin Drug Design and Delivery Strategies.- Clinical Perspectives.- Clinical Experience With 9-Aminocamptothecin.- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin).- Irinotecan.- Clinical Experience With Topotecan.- The Clinical Development of Lurtotecan.- Preclinical and Clinical Development of Exatecan (DX-951f).- Camptothecins in the Treatment of Primary Brain Tumors.- Camptothecins in the Treatment of Lung Cancer.- Use of Camptothecins in the Treatment of Leukemia and Related Disorders.